Solid Biosciences Llc Stock Alpha and Beta Analysis
| SLDB Stock | USD 6.76 0.53 8.51% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Solid Biosciences LLC. It also helps investors analyze the systematic and unsystematic risks associated with investing in Solid Biosciences over a specified time horizon. Remember, high Solid Biosciences' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Solid Biosciences' market risk premium analysis include:
Beta 1.89 | Alpha 1.37 | Risk 7.06 | Sharpe Ratio 0.2 | Expected Return 1.44 |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Check out Solid Biosciences Backtesting, Solid Biosciences Valuation, Solid Biosciences Correlation, Solid Biosciences Hype Analysis, Solid Biosciences Volatility, Solid Biosciences History and analyze Solid Biosciences Performance. Solid Biosciences Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Solid Biosciences market risk premium is the additional return an investor will receive from holding Solid Biosciences long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Solid Biosciences. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Solid Biosciences' performance over market.| α | 1.37 | β | 1.89 |
Solid Biosciences expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Solid Biosciences' Buy-and-hold return. Our buy-and-hold chart shows how Solid Biosciences performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Solid Biosciences Market Price Analysis
Market price analysis indicators help investors to evaluate how Solid Biosciences stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Solid Biosciences shares will generate the highest return on investment. By understating and applying Solid Biosciences stock market price indicators, traders can identify Solid Biosciences position entry and exit signals to maximize returns.
Solid Biosciences Return and Market Media
The median price of Solid Biosciences for the period between Fri, Apr 25, 2025 and Thu, Jul 24, 2025 is 4.31 with a coefficient of variation of 27.05. The daily time series for the period is distributed with a sample standard deviation of 1.12, arithmetic mean of 4.13, and mean deviation of 0.98. The Stock received a lot of media exposure during the period. Price Growth (%) |
| Timeline |
1 | Barclays Adjusts Price Target for Solid Biosciences Amid Progress SLDB Stock News | 05/16/2025 |
2 | Disposition of 3079 shares by Jessie Hanrahan of Solid Biosciences at 3.96 subject to Rule 16b-3 | 05/29/2025 |
3 | Acquisition by Howton David T of 58750 shares of Solid Biosciences subject to Rule 16b-3 | 06/09/2025 |
4 | Acquisition by Sullivan Lynne Marie of 77500 shares of Solid Biosciences at 4.58 subject to Rule 16b-3 | 06/12/2025 |
5 | Acquisition by Nagendran Sukumar of 77500 shares of Solid Biosciences at 4.58 subject to Rule 16b-3 | 06/13/2025 |
6 | Solid Biosciences Plunges 10.64 percent Amid Mixed Earnings Outlook - AInvest | 06/16/2025 |
7 | Sarepta Drops 42 percent on Fatalities Markets Eye Solid Biosciences | 06/18/2025 |
8 | Solid Biosciences Poised for Growth Amid Competitive Shifts SLDB Stock News | 06/26/2025 |
9 | Solid Biosciences Coverage Initiated by Analysts at Citigroup - MarketBeat | 06/30/2025 |
10 | Disposition of 4573 shares by Smith Ian F of Solid Biosciences subject to Rule 16b-3 | 07/03/2025 |
11 | Solid Biosciences Announces FDA IND and Health Canada CTA Approval for First-in-Class Cardiac Gene Therapy to Treat Catecholaminergic Polymorphic Ventricular Ta... | 07/08/2025 |
12 | Citi Initiates Coverage on Solid Biosciences Inc. with Buy Rating and 14 PT | 07/09/2025 |
13 | SHAREHOLDER NOTICE Kaskela Law LLC Announces Shareholder Investigation of Solid Biosciences Inc. and Encourages Long-Term SLDB Investors to Contact the Firm - P... | 07/10/2025 |
14 | Acquisition by Brooks Gabriel of 112900 shares of Solid Biosciences subject to Rule 16b-3 | 07/16/2025 |
15 | Solid Biosciences gets FDA fast track status for heart disease therapy | 07/23/2025 |
About Solid Biosciences Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Solid or other stocks. Alpha measures the amount that position in Solid Biosciences LLC has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2024 | 2025 (projected) | Payables Turnover | 0.58 | 0.55 | Days Of Inventory On Hand | 33.64 | 29.9 |
Solid Biosciences Upcoming Company Events
As portrayed in its financial statements, the presentation of Solid Biosciences' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Solid Biosciences' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Solid Biosciences' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Solid Biosciences. Please utilize our Beneish M Score to check the likelihood of Solid Biosciences' management manipulating its earnings.
| 28th of March 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 28th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Solid Biosciences
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Solid Biosciences Backtesting, Solid Biosciences Valuation, Solid Biosciences Correlation, Solid Biosciences Hype Analysis, Solid Biosciences Volatility, Solid Biosciences History and analyze Solid Biosciences Performance. You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.
Solid Biosciences technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.